MANUEL DOMAGTOY: Open Payments
NPI 1730511221 · SEBASTIAN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$602 in 18 payments from 9 companies in 2025. Trend: 2023 $733 · 2024 $445 · 2025 $602
Food & beverage: $602
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $156 |
| Gilead Sciences, Inc. | 1 | $121 |
| ABBVIE INC. | 4 | $76 |
| Braintree Laboratories, Inc. | 2 | $67 |
| Novo Nordisk Inc | 2 | $50 |
| Ardelyx, Inc. | 2 | $47 |
| PFIZER INC. | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
Products named: REZDIFFRA, Livdelzi, SUFLAVE, LINZESS, IBSRELA, VELSIPITY, RELISTOR, Ozempic.
Industry payments across FL — which companies pay providers there.
